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Abstract
Introduction: Tamoxifen is the most widely prescribed anti-estrogen treatment for patients with estrogen receptor 
(ER)-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in 
breast cancers and these may well be expressed in a dynamic manner.
Methods: In this study we assessed gene expression changes at multiple time points (days 1, 2, 4, 7, 14) after tamoxifen 
treatment in the ER-positive ZR-75-1 xenograft model that displays significant changes in apoptosis, proliferation and 
angiogenesis within 2 days of therapy.
Results: Hierarchical clustering identified six time-related gene expression patterns, which separated into three 
groups: two with early/transient responses, two with continuous/late responses and two with variable response 
patterns. The early/transient response represented reductions in many genes that are involved in cell cycle and 
proliferation (e.g. BUB1B, CCNA2, CDKN3, MKI67, UBE2C), whereas the continuous/late changed genes represented the 
more classical estrogen response genes (e.g. TFF1, TFF3, IGFBP5). Genes and the proteins they encode were confirmed 
to have similar temporal patterns of expression in vitro and in vivo and correlated with reduction in tumour volume in 
primary breast cancer. The profiles of genes that were most differentially expressed on days 2, 4 and 7 following 
treatment were able to predict prognosis, whereas those most changed on days 1 and 14 were not, in four tamoxifen 
treated datasets representing a total of 404 patients.
Conclusions: Both early/transient/proliferation response genes and continuous/late/estrogen-response genes are 
able to predict prognosis of primary breast tumours in a dynamic manner. Temporal expression of therapy-response 
genes is clearly an important factor in characterising the response to endocrine therapy in breast tumours which has 
significant implications for the timing of biopsies in neoadjuvant biomarker studies.
Introduction
The majority of human breast cancers express estrogen
receptor alpha (ERα) and are estrogen responsive [1].
Tamoxifen is still the most widely prescribed anti-estro-
gen for patients with ER-positive breast cancer and has
improved survival in women initially receiving this drug
as adjuvant therapy [2]. However, although the majority
of women respond to this agent, not all patients benefit
and there is a need to identify with greater precision
which tumors are sensitive and responding to this ther-
apy. Dynamic changes in specific marker genes in biopsy
material at early treatment points could be informative
and might indicate whether a tumor is likely to regress or
progress.
Although many in vitro studies have explored estrogen-
and tamoxifen-regulated changes on gene expression [3-
7], we are unaware of any xenograft studies that have
investigated the temporal regulation of expression
changes produced by tamoxifen in an ER-positive model
in vivo. Previous attempts to characterize the gene
expression response to tamoxifen in breast tumors in vivo
have been limited to single time points [8,9]. A recent
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Page 2 of 13time course experiment demonstrated dynamic gene
expression changes in response to estradiol (E2) in ZR-75-
1 cell lines in vitro [10]. Xenograft models allow assess-
ment of dynamic changes in tissue gene expression at
multiple time points from tissue, which is not feasible in
the clinical setting. Furthermore, an in vivo model allows
the effect of stromal elements and matrix elements to
contribute to expression, which cannot be easily repro-
duced in vitro.
A number of studies have investigated whether differ-
ences in gene expression in primary tumors (prior to
treatment) are associated with or can predict the
response to tamoxifen [11-13]. Vendrell and colleagues
recently described a candidate molecular signature asso-
ciated with tamoxifen failure in primary breast cancer by
examining gene expression in tumors following tamox-
ifen treatment [14]. An alternative to measuring gene
expression differences in the primary static situation is to
compare tumor biopsies matched before and after treat-
ment in so-called neoadjuvant 'window of opportunity
studies' [15]; these are likely to generate interesting
results in the near future.
We have previously used the ER-positive ZR-75-1
breast cancer xenograft model to demonstrate that
tamoxifen causes significant changes in apoptosis, prolif-
eration and angiogenesis within two days of initiating
therapy, which both antedated any evidence of growth
response and persisted for up to 14 days [3,16]. Here we
present the first study to look at the dynamic changes in
gene expression using multiple time points following
treatment with tamoxifen in vivo in order to better
understand the temporal response to therapy.
Materials and methods
Cell culture
The ZR-75-1, MCF-7 and MDA-MB-231 breast cancer
cell lines were obtained from the American Type Culture
Collection. Cells were maintained in DMEM (Life Tech-
nologies, Paisley, Scotland) containing 10% heat-inacti-
vated FCS, penicillin (100 units/mL), and streptomycin
(100 μg/mL). Cells were maintained routinely at 37°C in a
humidified atmosphere of 5% carbon dioxide in air. Forty-
eight hours before treatment, medium was changed to
phenol-red-free DMEM containing 5% double charcoal
stripped FCS, glutamine (2 mM), penicillin (100 U/ml)
and streptomycin (100 μg/ml). For temporal analysis of
gene expression, ZR-75-1, MCF-7 and MDA-MB-231
were incubated with 0.1 nM 17 β-E2 and/or tamoxifen (1
μM) (Sigma-Aldrich Chemical Co St. Louis, MO, USA) or
in serum-free medium alone for 0, 6 and 24 hours.
Xenograft experiment
All mouse experiments were performed in accordance
with Home Office guidelines. For the xenograft studies,
the ZR-75-1 cell line was first implanted into female nu/
nu mice. Animals received a subcutaneous slow-release
E2 pellet (0.72 mg released over 60 days, Innovative
Research of America, Sarasota, FL, USA) on the day of
tumor implant. The tumor was then maintained subcuta-
neously in the flanks of recipient animals by passaging 1
mm3 fragments as required, approximately every eight
weeks. For microarray experiments, ZR-75-1 fragments
were implanted subcutaneously into animals and allowed
to grow to a mean size of 0.25 cm3. All animals received
E2. On day 0, animals were randomly allocated to tamox-
ifen (2.5 mg released over 60 days, Innovative Research of
America, Sarasota, FL, USA) or E2-only control groups.
There were 20 mice, with tumors in each flank, in both
the control and treatment groups of this experiment.
Tumor volumes were measured using vernier callipers.
Bidimensional tumor diameters were recorded and vol-
umes calculated as vol = πDd2/6, where D is the larger of
the two diameters. Four mice from each group were sac-
rificed at each time point.
RNA extraction
Tumor xenografts treated with E2-only or E2 and tamox-
ifen were obtained from animals sacrificed on days 0, 1, 2,
4, 7 and 14. These were homogenized in lysis buffer and
total RNA was extracted using the Qiagen RNeasy® kit
(Qiagen, Valencia, CA, USA), according to the manufac-
turer's instructions. The concentration and purity of
RNA were determined by measuring spectrophotometric
absorption at 260 to 280 nm. To verify the integrity of the
total RNA, the samples were electrophoresed on a 1%
agarose gel in RNA loading buffer. A pool of total RNA
from xenografts collected on days 0, 1, 2 and 4, treated
with E2 only, was used as the reference population for all
cDNA microarray hybridisations. This provided an inter-
nal standard when compared with each experimental
sample.
Probe preparation, labelling, hybridisation and scanning of 
microarrays
Total RNA (100 ug), spiked with a bacterial-RNA mixture
for control, was used to prepare direct Cy3- and Cy5-
labelled first-strand cDNA probes using a single-base
anchored oligo dT17 primer (Sigma, St. Louis, MO, USA)
and Superscript II reverse transcriptase (Invitrogen,
Carlsbad, CA, USA). Unincorporated nucleotides were
removed using QIAquick PCR purification kit (QIAGEN,
Valencia, CA, USA) and Cy3- and Cy5-labelled probes
were coprecipitated with 16 μg human Cot 1 DNA (Invit-
rogen, Carlsbad, CA, USA) and 8 μg polyA (Sigma, St.
Louis, MO, USA). The pellets were resuspended in 8 μl of
H2O and 40 μl of hybridization buffer (5 × Saline-Sodium
Citrate (SSC), 6 × Denhardt's solution, 60 mM Tris HCl
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minutes and cooled at room temperature for 10 minutes.
The mix was overlaid with a coverslip and hybridized at
47°C for 12 to 24 hours in a humidified atmosphere to
Sanger Hver 1.3.1 cDNA microarrays (Sanger, Cam-
bridge, UK) as part of the CRUK/LICR Microarray Con-
sortium, contain 9,930 sequence-validated cDNA clones
representing approximately 6,000 unique sequences.
Microarrays were washed sequentially with 2 × SSC, 0.1 ×
SSC/0.1% SDS, and 0.1 × SSC and were air-dried by
briefly spinning in a centrifuge to remove excess liquid.
Fluorescent images of hybridized microarrays were cap-
tured using a ScanArray Express 3.0 scanner and ScanAr-
ray software (both from Perkin Elmer Waltham, MA,
USA).
Analysis of microarray data
Comparisons were made between pooled E2 only-treated
controls and E2 plus tamoxifen-treated samples across the
following time points - days 1, 2, 4, 7 and 14 - and
included reciprocal dye labelling to exclude gene-specific
dye bias. Expression ratios (Cy5/Cy3) were calculated fol-
lowing background correction using the R programming
language [17] and the BioConductor [18] package limma
[19] to account for dye bias. Intensity dependant (Loess)
and quantile normalization were also performed. Fold
changes were calculated as the relative mean difference
between treated and untreated dye-swap replicates. Nor-
malized data and raw gene expression files are publicly
available from in NCBI's Gene Expression Omnibus
(GEO) [20] and are accessible through GEO Series acces-
sion number GSE22386. Clustering was performed using
the Cluster and TreeView [21] programs. Kaplan Meier
analysis was performed using SPSS version 14 (an IBM
Company, Chicago, IL, USA). Estrogen-response ele-
ments (EREs) were identified using the Dragon program
[22]. Genes with the greatest prognostic power were
identified using supervized principle components analy-
sis [23] using version 3.5 of BRB ArrayTools [24] as previ-
ously described [12]. The Database for Annotation,
Visualization and Integrated Discovery (DAVID) [25] was
used to identify KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathways and Gene Ontology terms that were
significantly over-represented in gene lists above the level
expected by chance.
Validation of targets by quantitative RT-PCR
The expression of putative tamoxifen-regulated genes in
the ER-positive cell lines ZR-75-1 and MCF7 and the ER-
negative cell line MDA-MB-231 was performed by quan-
titative RT-PCR. Cells were maintained as outlined
above. A specific set of primers was designed for each tar-
get [see Additional File 1]. Total RNA was extracted from
log-phase cells using TRI reagent (Sigma, Poole, UK) fol-
lowing the manufacturer's instructions and treated with
DNAse I (Roche, Indianapolis, IN, USA). RNA was ana-
lyzed by real-time RT-PCR using Rotorgene (Corbett
Research, San Francisco, CA, USA) and the QuantiTect
SYBR Green system (QIAGEN, Valencia, CA, USA)
according to the manufacturers' instructions. Thermal
cycling conditions were as follows: RT at 50°C for 30 min-
utes; PCR: polymerase activation 95°C for 15 minutes,
followed by 40 cycles of denaturation at 94°C for 15 sec-
onds, annealing at 57°C for 30 seconds and extension at
72°C for 45 seconds. After a final extension at 72°C for 5
minutes, the melt profile was obtained across a 65°C to
99°C ramp, with 5 second ramps of 1°C. All reactions
were performed in triplicate for standard curve samples
and in quadruplicate for experimental and negative (no
template) samples. Analysis and quantification was per-
formed using Rotorgene v6 software. Relative quantifica-
tion was calculated by extrapolation of the standard curve
and calculation of ratio levels compared with β-Actin.
Immunohistochemistry
All experiments involving human tissues were conducted
with the permission of the local medical ethics advisory
board. A series of women over the age of 70 years with
large operable or locally advanced primary breast cancer
without metastatic disease presenting to the Edinburgh
Breast Unit between October 1991 and October 1993
have previously been described [26]. All had tumors
greater than 2 cm in maximum diameter, confirmed as
ER-positive invasive breast cancer. All patients received
20 mg tamoxifen daily for three months. Tumor size was
monitored by ultrasound measurements, and clinical
response defined as the percentage volume reduction
between the initial and final tumor volumes at three
months.
Formalin fixed paraffin-embedded blocks from the ini-
tial wedge biopsy and at definitive loco-regional surgery
three months later were available for 28 of these patients
and 3 μm tissue sections were cut. Formalin-fixed paraf-
fin embedded (FFPE) blocks were also available from the
original parallel xenograft study, which analyzed prolifer-
ation and apoptosis changes after tamoxifen treatment in
the ZR-75-1 xenograft [3]. Sections were deparaffinized
and rehydrated by standard methods and endogenous
peroxidase activity blocked by incubation in 3% H2O2 for
30 minutes. Sections were immersed in citrate buffer
(0.005 M, pH 6.0) and microwaved three times for five
minutes and then allowed to stand for 20 minutes. Slides
were washed in 0.05 M Tris/NaCl buffer (pH 7.6) and
then incubated in 20% FCS for 10 minutes prior to the
addition of the primary antibodies at room temperature
for 90 minutes in a humidified container. Optimal condi-
tions for antigen retrieval, and primary antibody dilutions
were previously determined for each antibody, as follows:
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Page 4 of 13trefoil factor (TFF) 3 (1/5, Calbiochem, Nottingham, UK),
PDZK1 (1/10, Abnova, Taipei City Taiwan), insulin
growth factor receptor binding protein (IGFBP) 4 (17661,
US Biological, Swampscott, MA, USA; 1:3 dilution) and
IGFBP5 (Ab4255, Abcam Cambridge, MA, USA; 1:300
dilution). After primary antibody incubation, sections
were washed in Tris/NaCl buffer for 10 minutes. A
Streptavidin-biotin multilink method (StrAviGen Mul-
tilink kit; Biogenex, San Ramon, CA, USA) was used for
detection. The sections were incubated with secondary
multilink antibody (1:20 dilution for 30 minutes) followed
by a horseradish-peroxidase-labelled streptavidin com-
plex (1:20 dilution for 30 minutes) at room temperature.
Diaminobenzidine tetrachloride was applied for five min-
utes prior to washing in water for two minutes. Slides
were then counterstained in hematoxylin, dehydrated and
mounted. Expression was measured using a scoring sys-
tem consisting of the product of the percentage of posi-
tive cells and their intensity of staining (0 to 3) producing
a Histoscore ranging from 0 to 300. All tumor cells in the
section were counted in the scoring system. Sections
were scored by three independent readers and mean val-
ues obtained. Where initial scoring produced a value
divergent by more than 10%, these sections were rescored
until agreement was reached.
Results
Dynamic changes in gene expression produced by 
tamoxifen
The effect of tamoxifen on tumor volume growth and
gene expression were studied on days 1, 2, 4, 7 and 14
after initiation of tamoxifen treatment and compared
with tumors grown in the absence of tamoxifen. Tumor
volumes were expressed relative to the initial tumor vol-
ume (Figure 1a). A reduction in tumor volume was clearly
evident at day 7 and by day 14 the curves had significantly
diverged. The graphs are significantly different at day 14
and are diverging by day 7 (P < 0.05; Student's t-test).
Across the five time points, 333 probes representing
253 genes showed evidence of at least a 1.5-fold change in
level of expression (using a P ≤ 0.05) [full list in the Addi-
tional File 1]. There was good agreement between the
expression levels of xenograft replicates at most time
points and the pattern of expression of these genes over
the five time points was most consistently separated into
six sets using hierarchical clustering (Figure 1b). These
six sets of differentially expressed genes can be divided
into three general groups: early/transient response (sets 1
and 2), variable response (sets 3 and 4) and continuous/
late response (sets 5 and 6), relative to untreated samples.
The early/transient-response genes were repressed rela-
tive to untreated samples, the variable-response genes
were initially induced and then repressed and the contin-
uous/late-response genes were both repressed (set 5) and
induced (set 6). A large percentage of the genes in set 1
were very strongly associated with cell cycle regulation,
among them AURKA, BUB1B, CCNA2, CDC25B,
CDKN3, CENPF, CDC28, CKS2, DLG7, MKI67, NEK2,
PRC1, STMN1, TACC3, UBE2C and ZWINT. BUB1,
CKS2, PRC1, UBE2C and ZWINT have previously been
shown to be estrogen-regulated in model systems [27].
Set 2 genes included mini-chromosome maintenance
(MCM) 2 and MCM6, components of the replication fork
[28], which may account for a primary response soon
after treatment reducing DNA replication and regulation.
Another member of set 2 was IGFBP4, which has been
widely detected in breast tumors and cell lines, and previ-
ously correlated with ER expression [29].
Most of the variable-response genes in sets 3 and 4
responded rapidly to tamoxifen treatment, although they
were both up- and down-regulated with some variation
between replicates. The genes in set 3 were predomi-
nantly involved in cell proliferation, adhesion, and apop-
tosis including BTG2, MYB, MYBL2 and CELSR1,
whereas genes in set 4, such as IRS and IGFR1 are
involved in insulin receptor signalling. Set 5 and set 6
represent genes with the greatest down- and up-regula-
tion at day 14, respectively (Figure 1b). Set 5 contained
many classical ER-response genes including TFF1, TFF3
and MYC. Serpins A1, A4 and A6 were also strongly
down-regulated. These genes play a key role in the con-
trol of tissue homeostasis and have previously been
shown to be up-regulated in response to E2 in normal
human breast tissue [30]. The cluster of up-regulated
genes in set 6 was the largest cluster representing a wide
variety of signalling pathways and processes. EREs were
found in the promoter regions of a similar proportion (34
to 42%) of all six clusters of genes [genes shown in bold in
the Additional File 1]. Studies by Carroll and colleagues
have shown that ERs only sometimes regulate genes using
EREs from proximal promoter regions and generally use
distal enhancers and other binding sequences, such as
Forkhead binding sites [31]. The observation of 34 to 42%
of genes containing EREs in their promoter regions is
consistent with these studies.
Tamoxifen response compared with the response to 
estradiol over time
Many of the genes identified as changing in response to
tamoxifen have also been identified in previous single
time-point experiments, either in the opposite direction
in response to 17β-E2 or in the same direction with
tamoxifen in both in vivo and in vitro studies [8,30]. In
order to establish whether the dynamic changes observed
in this study reflected the reverse of the response to E2
over time, we compared our results with those from an in
vitro time-course experiment, which also utilized the ZR-
75-1 cell line [10]. Although that study had 12 time-
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Figure 1 Changes in gene expression over time in tamoxifen-treated xenografts. (a) Comparison of the change in tumor volume over time in 
tamoxifen-treated and untreated (estrogen-supplemented) xenograft tumors. Values are the mean of four xenografts and error bars represent the 
standard error. (b) Heatmap illustrating genes with significantly increased (red) or decreased (green) expression in response to tamoxifen in the xe-
nografts relative to no treatment. Underlined genes are those predicted to have estrogen-response elements (EREs) in their promoter regions. (c) 
Change in mean expression level (log2 fold change) of genes over time in xenografts treated with 17β-estradiol and tamoxifen (red). The changes 
shown in blue are those reported by Mutarelli and colleagues for 17β-estradiol alone [10].
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addition of E2, the vast majority of genes showed the
expected reciprocal changes in expression to those seen
in the six clusters for the initial time points following
treatment with tamoxifen in the present study (Figure
1c).
Gene expression changes in vitro
To obtain further confirmation that the expression
changes observed in response to tamoxifen were valid, 15
genes were selected for in vitro validation. These were
analyzed in ZR-75-1 cells treated with either 0.1 nM E2 or
1 μM tamoxifen or both agents together to assess
whether the genes were not only tamoxifen-regulated but
also estrogen-regulated and whether tamoxifen was
antagonising the estrogen-modulation or working via
some other mechanism. A second ERα-responsive cell
line, the MCF-7 line, was also used to assess whether the
expression changes could be observed in an independent
genotype. The ERα-negative cell line, the MDA-MB-231
line, was used to assess the specificity of these changes to
involvement of ERα. Expression changes were measured
at both 6 and 24 hours [Additional File 2]. The gene
expression changes that were observed in vivo were also
observed in these in vitro experiments and the changes
seen in ZR-75-1 cells were mirrored in MCF-7 cells (Fig-
ure 2). Rather than reversing the expression change pro-
duced by E2, IER3 produced a greater change in the same
direction. In contrast, there were no significant changes
for any of these genes in the MDA-MB-231 cell line (Fig-
ure 2).
Dynamic changes in protein expression within the ZR-75-1 
xenograft model
Four candidate genes were selected to evaluate whether
expression changes at the protein level over time within
this xenograft model were consistent with those seen at
the gene expression level (Figure 3a). MCM2 and CKS2
were chosen as examples of early/transiently changing
cell cycle-associated genes (sets 1 and 2). IGFBP5 and
TFF3 were selected as examples of late/continuously up-
and down-regulated genes, respectively (sets 5 and 6).
Sections of the xenografts were assessed by semi-quanti-
tative immunohistochemistry and histoscores related to
the initial values. The protein expression of MCM2 and
CKS2 had a similar profile to that seen at the gene expres-
sion level, although protein expression was higher at day
21 than at 0 and 14 days with gene expression. TFF3
expression decreased with time whereas IGFBP5 expres-
sion increased (Figure 3a).
Protein expression changes in breast cancers treated with 
tamoxifen
To establish whether the change in expression of identi-
fied proteins correlated with changes seen in vivo, a series
of primary breast cancers for which material was avail-
able pre- and post-tamoxifen treatment and in which the
response at three months had been measured were ana-
lyzed by immunohistochemistry. Four proteins were
selected (IGFBP5, TFF3, IGFBP4 and PDZK1) to repre-
sent the early/transient and later/continuous patterns of
expression seen at the transcript. Breast cancer samples
pre- and post-tamoxifen treatment were available for 28
patients and information on the percentage change in
tumor volume was known. Change in histoscores in pre-
and post-treatment paired samples were compared with
the change in tumor volume (Figure 3b). The change in
IGFBP5, TFF3 or both was significantly associated with
change in tumor volume (P = 0.0135, 0.018 and 0.0002,
respectively; Spearman rank test). This contrasted with
data for IGFBP4 and PDZK1 where there was no signifi-
cant association. PDZK was selected as a known estro-
gen-regulated gene that has been identified within a
number of clinical data sets [32,33].
Are the dynamically changing genes able to predict 
prognosis?
To evaluate whether the genes identified as dynamically
changing in response to tamoxifen are associated with
long-term follow up we downloaded four Affymetrix pri-
mary breast tumor datasets [11,34,35] from the NCBI
GEO for patients that had all been treated with tamoxifen
and for whom corresponding outcome data were avail-
able (Table 1). Affymetrix probesets representing the
genes in the six gene sets with similar temporal profiles of
expression were identified and clustered to separate
tumors with high or low expression of each set of repre-
sentative probesets [Additional File 3], as described pre-
viously [36]. Kaplan Meier plots were generated and log
rank (Mantel-Cox) statistics calculated to see if the level
of these sets of genes could discriminate between patients
with good or poor outcomes. The set 1 cluster of genes
was highly prognostic with all four datasets. Set 2, set 4
and all six gene sets combined also had some predictive
power, although this was not consistent across the four
datasets (Table 1). The genes driving this prognostic sep-
aration appear to be those involved with cell cycle and
proliferation, patients with high levels of these genes at
presentation are known to be at high risk of recurrence
[13]. Additional File 3 illustrates the level of expression of
the tamoxifen-response genes in primary tumors at pre-
sentation. Of the genes in set 1, one-third (11 out of 32)
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Figure 2 In vitro gene expression in two ER+ and one ER- cell line at 24 hours following treatment with tamoxifen. Quantitative RT-PCR results 
for ZR75 (royal blue), MCF7 (dark blue) and MDA-MB-231 (red) with no treatment (control), addition of estradiol, tamoxifen or estradiol plus tamoxifen 
(changes at 6 hours and further genes shown in Additional File 2). ER, estrogen receptor.
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Page 8 of 13are represented in the 97 gene Genomic Grade Index that
is undoubtedly associated with prognosis [35]; set 1 genes
were also able to clearly distinguish between the histolog-
ical grade of the tumors.
Do the genes that are most changed at independent time 
points following treatment with tamoxifen predict 
prognosis?
Different numbers of probes were identified to be signifi-
cantly differentially expressed at each time point. In order
to compare the relative prognostic value of a profile of
genes that are most changed at an individual time point
following treatment, we identified lists of 50 probes with
the greatest fold changes (up or down) at each time point
among the list of 333 most changed probes as described
above. Some probes were most changed at more than one
time point [see Additional File 1]. Patients whose gene
expression profile at presentation was more like that of
xenograft tumors following treatment had a poorer prog-
nosis [see Additional File 3]. Figure 4 demonstrates that
profiles of the most differentially expressed genes at two,
four and seven days following tamoxifen treatment were
able to predict prognosis, while lists of genes most
changed initially (day 1) or later (day 14) cannot. None of
these most changed gene lists were significantly prognos-
tic in two datasets [37,38] of ER-positive tumors that did
not receive adjuvant therapy (Figure 4). Supervized prin-
ciple components analysis [23] was also used to identify
which genes within the profiles have the greatest prog-
nostic power. The genes changed at each of the five inde-
pendent time points were dominated by the late/
continuously up- and down-regulated genes (sets 1 and
2), with early changes (sets 5 and 6) less represented and
the transient changes hardly represented at all [see Addi-
tional File 1]. Known estrogen-response genes including
IGFBP5, TFF3, TFF1, PDZK1 and SERPINA genes appear
to dominate in prognostic performance. IGFBP5 expres-
sion is higher in patients with poor prognosis, as noted
previously [29,39]; however, it is not significantly changed
at day one, but is at subsequent time points, as seen at the
protein level (Figure 3a). The heatmaps in Additional File
3 also indicate that IGFBP5 may be a good biomarker of
outcome on tamoxifen.
Discussion
This study is, to the best of our knowledge, the first to
define tamoxifen-regulated gene expression profiles at
multiple time points after long-term anti-estrogen treat-
ment in an in vivo model of ER-positive breast cancer.
The use of multiple time points over the 14-day period
allowed analysis of the temporal patterns of gene expres-
sion profiles. Three basic patterns of change were
observed; early/transient changes, continuous/late
changes and more variable changes. The pattern of
expression of representatives of these sets of genes was
confirmed by quantitative RT-PCR and at the protein
level by semi-quantitative immunohistochemistry. The
changes observed in the expression of IGFBP5 and TFF3
correlated with reductions in tumor volume in primary
Figure 3 Temporal protein expression of genes identified to re-
spond to tamoxifen in vivo. MCM2, CKS2, IGFBP5 and TFF3 have sim-
ilar expression at the protein level in response to tamoxifen in the ZR-
75 xenograft by semi-quantitative immunohistochemistry. (a) They 
represent two pairs of examples of early/transiently and later/continu-
ously responding proteins respectively. The correlation between the 
change in expression of proteins identified in the study and change in 
tumor volume in 28 patients treated with tamoxifen was calculated. 
Protein levels were scored by immunohistochemistry in tumor sam-
ples taken before and three months after treatment with tamoxifen. 
Changes in protein score are plotted relative to reduction in tumor vol-
ume for (b) IGFBP5 and (c) TFF3.
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Page 9 of 13tumors treated with tamoxifen. Two different approaches
were used to evaluate whether those genes for which
there was clear evidence of tamoxifen-induced changes in
expression level would themselves be prognostic for
patients treated with adjuvant tamoxifen. The early/tran-
sient pattern of gene expression associated with a reduc-
tion in cell cycle/proliferation genes and genes that were
most differentially expressed on days two, four and seven
were able to predict prognosis of primary breast tumors
treated with tamoxifen. The IMPACT (Immediate Preop-
erative Arimidex Compared to Tamoxifen) trial demon-
strated that Ki67 level two weeks after treatment was
predictive of long-term outcome [40]. The timing of mea-
surement of gene expression changes appears to be criti-
cal for certain groups of genes. A number of neoadjuvant
'window of opportunity studies' are underway to charac-
terize changes in gene expression in response to treat-
ment and establish whether clinical response after a
couple of weeks or several months is predictive of long-
term outcome. Studies such as that described here may
provide insights as to when significant changes are
detectable and which genes may represent good markers
of response. It also highlights the risk that clinical snap-
shots of treatment could miss informative changes in
expression.
There have been multiple short-term studies of in vitro
profiling after estrogen treatment, predominantly in
MCF-7 cells [41,42] and also in ZR-75-1 cells [4,10]. In a
study using the T47D model of ER-positive breast cancer,
Harvell and colleagues stated that E2 regulates different
genes in human breast tumor xenografts compared with
the identical cells in culture [9]. However, Creighton and
Table 1: Prognostic capacity of the sets of dynamically changing genes in patients treated with tamoxifen
Study/dataset Tamoxifen-treated datasets Untreated datasets
Zhang and 
colleagues [11]
Loi and colleagues [34] Sotiriou and 
colleagues [35]
Wang and 
colleagues [37]
Desmedt and 
colleagues [38]
NCBI GEO dataset [20] GSE12093 GSE6532 GSE2990 GSE2034 GSE7390
Affymetrix GeneChip U133A U133A U133 plus2 U133A U133A U133A
No tumors
(All ER+ and TAM-treated)
136 119 87 62 209 134
Tumor grade (1/2/3/NA) 8/43/30/55 1/94/4/20 17/37/16/
17
32/0/27/3 NA 29/68/35/2
Age (median) 64* 65 63 66 52 47
Follow up (median) 7.1 5.2 11.4 4.9 7.2 10.4
Endpoint DFS RFS RFS RFS RFS DFS
All dynamic genes (sets 1 to 6) P = 0.7 P = 0.2 P = 0.0006 P = 0.1 P = 0.005 P = 0.6
Set 1 (early/transient) P = 0.00005 P = 0.0002 P = 0.0002 P = 0.002 P = 0.002 P = 0.04
Set 2 (early transient) P = 0.4 P = 0.3 P = 0.5 P = 0.03 P = 0.03 P = 0.2
Set 3 (variable) P = 0.8 P = 0.7 P = 0.2 P = 0.6 P = 0.0005 P = 0.1
Set 4 (variable) P = 0.5 P = 0.2 P = 0.008 P = 0.6 P = 0.7 P = 0.3
Set 5 (continuous/late) P = 0.1 P = 0.2 P = 0.1 P = 0.5 P = 0.1 P = 0.2
Kaplan-Meier (Mantel-Cox log rank) analysis of the endpoints; *Mean value. DFS, disease-free survival; ER, estrogen receptor; NA, not available; 
RFS, relapse-free survival; TAM, tamoxifen.
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Page 10 of 13colleagues found that genes regulated by estrogen in
breast tumor cells in vitro are similarly regulated in vivo
in tumor xenografts and human tumors [8]. Disparities
between approaches may be the result of differences in
time points as well as the differences in microenviron-
ment. Our in vitro study allowed exploration of whether
tamoxifen's effects were antagonistic to estrogen or not.
Fifteen genes were selected and all were modulated by
estrogen in vitro. Of these genes, tamoxifen reversed the
estrogen modulation in 14 cases but not for IER3. This
gene was of particular interest in that while it was estro-
gen up-regulated, tamoxifen produced a greater up-regu-
lation, it was also continuously up-regulated at all five
time points and among the genes of set 6.
Our previous study [3] demonstrated early changes in
apoptotic and mitotic indices (days 2 and 4) predated
tumor volume changes, we speculate that the earlier/
transient expression changes observed are more likely to
be causative and primary events for tumor volume inhibi-
tion whereas later/continuous expression changes are
possibly only consequential and secondary to the volume
changes. These may represent changes in stromal ele-
ments and infiltrating cell populations. Ongoing studies
are seeking to develop a putative model of how the early/
transient changes interact with the later/continuous
changes.
Many of the breast cancer gene expression signatures
that have previously been developed highlight a number
Figure 4 Prediction of prognosis of tamoxifen-treated tumors based upon the 50 highest responding genes at each independent in vivo 
time point. Kaplan-Meier analysis of four tamoxifen-treated and two untreated datasets [11,34,35,37,38], named by first author and the number of 
estrogen receptor (ER)-positive tumors with follow-up information (Table 1). Lists of genes are in Additional File 1. Green = primary tumors at presen-
tation with expression profiles most like treated xenografts; Blue = primary tumors at presentation with expression profiles less like those of tamoxifen-
treated xenografts.
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Page 11 of 13of genes associated with cell cycle and proliferation
[35,36,43-46], which has been suggested to be largely a
reflection of tumor grade. These genes appear to have
most prognostic value for ER-positive breast tumors,
generally differentiating between luminal A and luminal
B subtypes, both prior to or following treatment with
tamoxifen [13] or chemotherapy [47,48]. Our results are
consistent with this idea and the suggestion that a lower
response to E2 or growth factor signaling [49], also a fea-
ture of luminal B tumors, may also be prognostic. It is not
clear from our results the extent to which prognosis or
prediction of response to therapy is an intrinsic property
of tumors.
Relatively high levels of the set 1 pattern of dynamically
changing cell cycle/proliferation genes at presentation in
primary tumors was associated with poor prognosis;
however, it was relatively low levels of the classically up-
regulated E2-response genes (down-regulated by tamox-
ifen), such as TFF1, TFF3, AREG and IGFBP4, at presen-
tation that were among the genes most changed at day 4
and associated with poor prognosis. Conversely, a reduc-
tion in TFF3 (or an increase in IGFBP5) following tamox-
ifen treatment in vivo and the protein levels in primary
tumors correlated with a reduction in tumor volume in
the 28 patients treated with tamoxifen for three months.
This apparent contradiction between the direction of
change in genes upon treatment and their relative level in
primary tumors as long-term predictors of outcome may
be due to the complexity of estrogen signaling, the ago-
nistic and antagonistic roles of estrogen and tamoxifen on
the ER and/or a difference between short- and long-term
effects on both tumors and normal tissues. We also
recently demonstrated that proliferation genes were
strongly down-regulated following treatment with the
mTOR inhibitor, everolimus, despite these often being
considered markers of prognosis [50].
The aim of this study was to assess the dynamic
response to tamoxifen, not to find the definitive tamox-
ifen-response signature or biomarker. A better test of the
tamoxifen-response genes in primary tumors would be a
dataset from a neoadjuvant 'window study' [15] of gene
expression before and after tamoxifen with both clinical
or pathological endpoints and long-term follow-up. It
would be interesting to measure gene expression at multi-
ple time points in a number of different cell line xenograft
models or primary tumors in order to fully investigate
patient-patient variation in temporal response to tamox-
ifen. This approach would also benefit from single-color
microarrays in order to evaluate the relative merits of
pre- and post-treatment samples avoiding the limitation
of using comparative two-colour cDNA arrays, as in this
study. We did examine gene expression of the different
response patterns (sets 1 to 6) and individual time points
in matched before and after breast biopsies from patients
treated with 14 days of neoadjuvant letrozole [51] and
found largely consistent changes for most genes with
those of the in vivo study in the majority of cases (data
not shown). Further work is required to fully assess how
the response to different hormonal therapies and short-
term molecular changes correlate with long-term out-
come. We have previously demonstrated that estrogen-
regulated gene expression predicts response to endocrine
therapy in patients with ovarian cancer [27], and in this
study we demonstrate for the first time that tamoxifen-
response genes identified from a xenograft breast cancer
model with different profiles of expression can predict
prognosis in primary tumors treated with tamoxifen.
The genes highlighted in this study are now being
explored in clinical material collected by biopsy from
patients pre- and post-treatment with tamoxifen and who
are known to have either responded to or progressed on
treatment. This will help determine which of the genes
identified in this study have the potential to be predictive
markers of response. This study also suggests that future
studies searching for genes predictive of outcome on
therapy could perhaps be informed by studies that iden-
tify which genes demonstrate early dynamic response to
therapy, rather than those with sustained changes. This is
reminiscent of data from early positron emission tomog-
raphy (PET) scans that suggest the patients with the best
outcome on therapy are those with pronounced early
reduction in PET signal [52,53].
Conclusions
Both early/transient/proliferation-response genes and
continuous/late/estrogen-response genes are able to pre-
dict prognosis of primary breast tumors in a dynamic
manner. Temporal expression of therapy-response genes
is clearly an important factor in the response to endo-
crine therapy in breast tumors which has significant
implications for the timing of biopsies in neoadjuvant
biomarker studies.
Additional material
Additional file 1 Lists of differentially expressed genes. Microsoft Excel 
Workbook containing probe and gene names, plus Ensembl identifiers and 
mean fold changes for the 333 significantly differentially expressed probes. 
Also provided are lists of the 50 most changed genes at the five timepoints 
following treatment with tamoxifen.
Additional file 2 Quantitative PCR results. Gene expression in vitro mea-
sured by quantitative RT-PCR for ZR75 (royal blue), MCF7 (dark blue) and 
MDA-MB-231 (red) before (0), 6 and 24 hours following no treatment (C), 
addition of estradiol (E), tamoxifen (T) and estradiol plus tamoxifen (ET).
Additional file 3 Examples of heatmap clustering. Heatmaps showing 
the level of expression of the (a) set 1 and (b) day 4 tamoxifen-response 
genes in primary tumors at presentation. Patients whose expression of set 1 
genes correlate with post-treatment xenograft samples have a good prog-
nosis (blue). However, patients whose expression of genes at presentation 
is more like those that were differentially expressed at day 4 following 
tamoxifen treatment tend to have a poor prognosis (green). See Table 1 and 
Figure 4 for survival analysis results.
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